Effect of Gemcitabine combined with cisplatin neoadjuvant chemotherapy on clinical efficacy, adverse reactions and quality of life in locally advanced bladder cancer
Objective To analyze the effects of gemcitabine combined with cisplatin neoadjuvant chemotherapy on clinical efficacy, adverse reactions and quality of life of locally advanced bladder cancer. Methods Data of 82 patients with locally advanced bladder cancer admitted to our hospital from February 2019 to February 2021 were selected and divided into two groups according to random number table method. 41 patients in the control group received cisplatin treatment, and 41 patients in the study group received gemcitabine combined with cisplatin chemotherapy. The therapeutic effect, quality of life and occurrence of adverse reactions in the two groups were analyzed. Results The total effective rate of the study group was 90.24％, higher than 65.85％ of the control group, the difference was statistically significant (P＜0.05). After treatment, the quality of life score of the study group was (85.87±3.98) points, higher than that of the control group (73.46±4.29) points, and the difference was statistically significant (P＜0.05). The incidence of adverse reactions in the study group was 4.87％, which was lower than 19.51％ in the control group, and the difference was statistically significant (P＜0.05). Conclusion Gemcitabine combined with cisplatin can reduce adverse reactions and improve quality of life in patients with locally advanced bladder cancer.
GemcitabineCisplatin neoadjuvant chemotherapyadvanced bladder cancereffectquality of lifeadverse reaction
万方数据
